Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syn-Tech Chem & Pharm CoROCO:1777 +0.41%73 EV-to-FCF is 4.84 as of Jul. 21, 2026, which is 49% below its 10-year median of 9.45. GuruFocus rates ROCO:1777 with a GF Score™ of 73/100 and a GF Value™ of NT$106.95 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 338 Biotechnology companies, Syn-Tech Chem & Pharm Co ranks better than 64.2% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Syn-Tech Chem & Pharm Co's Enterprise Value is NT$2,425 Mil.
Syn-Tech Chem & Pharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$501 Mil. Therefore, Syn-Tech Chem & Pharm Co's EV-to-FCF for today is 4.84.
The historical rank and industry rank for Syn-Tech Chem & Pharm Co's EV-to-FCF or its related term are showing as below:
ROCO:1777'
s EV-to-FCF Range Over the Past 10 Years
Min: -545.63 Med: 9.45 Max: 91.99
Current: 4.74
During the past 13 years, the highest EV-to-FCF of Syn-Tech Chem & Pharm Co was 91.99. The lowest was -545.63. And the median was 9.45.
ROCO:1777's EV-to-FCF is ranked better than 64.2% of 338
companies
in the Biotechnology industry
Industry Median: 15.02
vs ROCO:1777: 4.74
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Syn-Tech Chem & Pharm Co (ROCO:1777) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Syn-Tech Chem & Pharm Co's PE Ratio (TTM) for today is calculated as:
Syn-Tech Chem & Pharm Co's share price for today is NT$72.80.
Syn-Tech Chem & Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Syn-Tech Chem & Pharm Co EV-to-FCF Related Terms
Syn-Tech Chem & Pharm Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1777 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Syn-Tech Chem & Pharm Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syn-Tech Chem & Pharm Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syn-Tech Chem & Pharm Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Syn-Tech Chem & Pharm Co's EV-to-FCF falls into.
Syn-Tech Chem & Pharm Co's current Enterprise Value is NT$2,425 Mil.
Syn-Tech Chem & Pharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$501 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syn-Tech Chem & Pharm Co (ROCO:1777) has a EV-to-FCF of 4.84 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Syn-Tech Chem & Pharm Co and its competitors. This is 49% below median its historical median of 9.45. According to the industry distribution chart, Syn-Tech Chem & Pharm Co ranks #121 out of 338 companies in the Biotechnology industry, placing it in the top 35.8%.
Is Syn-Tech Chem & Pharm Co's EV-to-FCF too high?
Syn-Tech Chem & Pharm Co's current EV-to-FCF of 4.84 is 49% below median its 10-year median of 9.45. The Biotechnology industry median EV-to-FCF is 15.02. Syn-Tech Chem & Pharm Co's value of 4.84 is 67.8% below this industry median. Based on the distribution chart, Syn-Tech Chem & Pharm Co ranks #121 out of 338 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Syn-Tech Chem & Pharm Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syn-Tech Chem & Pharm Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn-Tech Chem & Pharm Co ranks #121 out of 338 companies for EV-to-FCF. This puts Syn-Tech Chem & Pharm Co in the upper half of its industry. The industry median EV-to-FCF is 15.02. Syn-Tech Chem & Pharm Co's value of 4.84 is 67.8% below this benchmark. While the company's 10-year median is 9.45 vs. the industry median of 15.02, Syn-Tech Chem & Pharm Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.02, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syn-Tech Chem & Pharm Co's current EV-to-FCF of 4.84 is 67.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Syn-Tech Chem & Pharm Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syn-Tech Chem & Pharm Co's current EV-to-FCF is 4.84, which is 49% below median its own 10-year median of 9.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn-Tech Chem & Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co (ROCO:1777) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$106.95, compared to a current price of NT$72.80 — trading 31.9% below its estimated fair value. The current EV-to-FCF is 4.84, which is 49% below median its 10-year median of 9.45 and 67.8% below the Biotechnology industry median of 15.02. Syn-Tech Chem & Pharm Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Syn-Tech Chem & Pharm Co (ROCO:1777), the current EV-to-FCF is 4.84 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syn-Tech Chem & Pharm Co (ROCO:1777) Overvalued in 2026?
Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co stock appears to be undervalued.
The current stock price of NT$72.80 is trading 31.9% below its estimated GF Value™ of NT$106.95.
GuruFocus considers Syn-Tech Chem & Pharm Co to be Significantly Undervalued.
Key valuation signals for ROCO:1777:
EV-to-FCF: 4.84 (49% below median its 10-year median of 9.45)
GF Value™: NT$106.95 vs. price of NT$72.80 (31.9% below fair value)
Industry Position: 67.8% below the Biotechnology median (#121 of 338)
No single metric tells the full story. See the ROCO:1777 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syn-Tech Chem & Pharm Co Ltd is engaged in the manufacture and sale of western medicines, veterinary drugs, food additives, cosmetics, and related businesses. It manufactures and sells Active Pharmaceutical Ingredients for domestic and foreign pharmaceutical companies and trade agents. Its products include Alfuzosin HCl, Atomoxetine HCl, Chlorzoxazone, Chlormezanone, Cloperastine HCl, Crotamiton, Diclofenac Epolamine, and others. It generates the majority of its revenue from Asia excluding Taiwan.
73GF Score
Get the complete analysis for ROCO:1777
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1777 has been successfully added to your 
